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Abstract
TIBLE is a web-based resource that provides easy access to data on the minimal inhibi-
tory concentrations for small molecules against several mycobacterial species, as well as
the target binding and off-target predictions for Mycobacterium tuberculosis. The current
version of the database holds the activity data for more than 19 000 distinct small
molecules against 39 mycobacterial species, binding data for 106 Mycobacterium tuber-
culosis target proteins and predictions for their potential off-targets. The resource
integrates disparate public data and methods to provide easy access to the minimum in-
hibitory concentration and binding data, facilitation of data sharing, and identification of
small molecules and targets for development of anti-tuberculosis therapeutics.
Database URL: http://www-cryst.bioc.cam.ac.uk/tible/
Introduction
The Mycobacterium genus includes various pathogenic and
non-pathogenic species, with thick cell walls, which are rich
in mycolic acid (http://www.bacterio.net/mycobacterium.
html). The pathogenic mycobacterial species cause serious dis-
eases in humans and other species, such as tuberculosis
(Mycobacterium tuberculosis), leprosy (Mycobacterium
leprae), ulcerated lesions (Mycobacterium ulcerans) and other
lung infections (Mycobacterium abscessus). Some of these
species, such as M. tuberculosis and M. leprae, are adapted to
survive only as obligate pathogens and hence have reduced
the size of their genomes, whereas other species, such as
M. abscessus (opportunist pathogen which affects pa-
tients with cystic fibrosis and other lung diseases) and
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M. smegmatis (non-pathogenic), have acquired genes through
horizontal gene transfer and consequently have larger gen-
omes. Here, we collate the small-molecule binding data for
all the mycobacterial species from ChEMBL database
(https://www.ebi.ac.uk/chembl/) and further map the
M. tuberculosis data to their respective protein targets.
Tuberculosis (TB), a disease caused by M. tuberculosis,
is one of the top ten causes of deaths worldwide (1). As a
result of the TB goals set by the World Health
Organisation (WHO) in 2000, a reduction in the mortality
rate of 47% has been reported and also the TB incidence
rate has dropped by 1.5% (2). These success stories can be
partly attributed to the implementation of effective data
collection, sharing and monitoring. However, in 2015, TB
was found responsible for the deaths of 1.4 million people,
with an additional 0.4 million deaths reported for HIV pa-
tients suffering from TB. Almost 0.6 million people were
infected in 2015 with either multidrug-resistant TB (MDR-
TB, 480 000 new cases) or rifampicin-resistant TB (RR-
TB, 100 000 new cases) (1).
The emergence of resistance to the existing antimicro-
bial drugs raises concerns over the success of the available
treatment methods. To tackle this, we need to discover
new drugs, repurpose old drugs and/or develop combin-
ation therapies. In order to do this, it would be beneficial
to have easy access to the available small-molecule binding
data for the target proteins of the species of interest.
Over recent years, the scientific community has wit-
nessed an increase in the number of open-source data re-
sources that encourage data sharing to facilitate the
discovery of new anti-mycobacterial drugs. These include
databases like ChEMBL (3) consisting of small bioactive
molecules, binding targets and assay data, DrugBank (4)
holding biochemical and pharmacological data for drugs,
PubChem (5) storing activities of small molecules against
biological assays, Collaborative Drug Discovery (CDD) (6)
recently supporting the MM4TB (More Medicines for
Tuberculosis) project (7), BindingDB (8) holding binding
affinities of small molecules to protein targets and
ChemBank (9) storing small molecule biological screening
data. These resources are reservoirs of information on the
activities of small molecules against a wide range of dis-
eases, protein targets and organisms. Amongst these, are
several databases that specifically focus on certain diseases
and/or the causative bacterial pathogen. There are several
resources for the M. tuberculosis genome such as
CHOPIN, a database of three-dimensional protein struc-
ture models for the M. tuberculosis proteome (10), SInCRe
a structural interactome computational resource for M. tu-
berculosis (11), TB Database platform, which holds cura-
ted genomic data and annotation for TB research (12),
TBdreamDB specializes in TB drug resistance mutation
data (13), Tuberculist provides the genome annotation for
M. tuberculosis H37Rv strain (14). However, little atten-
tion is being given to the other mycobacterial species and
there are only a few databases that provide information on
other mycobacterial species such as MabsBase (15) pro-
vides annotation for M. abscessus ATCC19977,
MycoBrowser (16) holds genomic and proteomic data for
M. tuberculosis, M. avium and M. abscessus and a recently
developed database MycoBase (17), which provides
updated annotations for eleven mycobacterial species
including both the pathogenic (such as M. leprae, M. bovis,
M. avium) and non-pathogenic species (such as M. smeg-
matis). Some of the resources that also include other bac-
terial species are the TDR Target Database (18), which
focuses on target identification for neglected tropical
disease pathogens or the MIC database (19) which has
500 records of antibiotic compounds for about 80 micro-
organisms. The databases that include other pathogenic
mycobacterial species are certainly useful for understand-
ing the pathogenesis and evolutionary relationships
between species. However, genome annotation of non-
pathogenic species can be equally valuable, as these can be
used as models to study the pathogenic species.
Extracting disease and organism specific datasets from
such resources remains a challenge to most researchers in
medicinal chemistry, life sciences and pharmacology, espe-
cially if they are not acquainted with the cheminformatics
tools or query languages, which are needed to extract the
precise and complete sets of data of interest. To contribute
towards the antituberculosis research efforts, we have col-
lated, processed and provided access to the relevant myco-
bacterial data i.e. Minimal Inhibitory Concentration
(MIC) and small molecule binding target data.
MIC is the lowest concentration (mg/l) of an antimicro-
bial that prevents the visible growth of a given strain of
bacteria under defined conditions, and is widely used in
basic research and pharmacology to determine the most ef-
fective starting point for the evaluation of an antibiotic for
a given organism and species (20). MIC data provide infor-
mation that can lead to an appropriate choice of an antibi-
otic, thereby increasing the chances of treatment success
(21). On the other hand, one of the main causes of the high
attrition rates in drug development is the non-clinical toxi-
cology (22). Proposed drug candidates often fail to be pro-
ven safe and therefore it is of paramount importance to
identify possible off-targets as early as possible in the dis-
covery pipeline.
Computational ligand-based and target-based structure-
guided methods have been widely applied to predict poten-
tial targets for various bioactive compounds (23). The data
obtained from these experiments have provided informa-
tion on off-target binding of drugs, polypharmacology and
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ways of reducing adverse drug interactions. To improve
visibility and access to the off-target data, some small-
molecule databases like ChEMBL have incorporated
information about the predicted targets for approved
drugs (24).
Here, we present TIBLE (http://www-cryst.bioc.cam.
ac.uk/tible/), a web-based resource that provides easy
access to MIC data for small molecules against several
mycobacterial species and binding data for specific pro-
tein targets for M. tuberculosis, including information
on potential off-target sites (Figure 1). The data from
TIBLE can be downloaded easily, thus encouraging data
sharing, and facilitating identification of anti-TB small




The primary source of data for TIBLE is the ChEMBL
database. ChEMBL currently contains nearly 1.7 million
distinct compounds, >11 000 targets, and >14 million
activities that are extracted from >65 000 publications (3).
ChEMBL can be accessed and downloaded as a relational
database in different formats through the European
Bioinformatics Institute’s website (https://www.ebi.ac.uk/
chembl/). A local copy of the current version, ChEMBL_22
(in PostgreSQL), has been used to derive the TIBLE re-
source. Bespoke SQL queries have been developed to ex-
tract and organize mycobacterial data into the TIBLE
database. MIC data points for mycobacterial species were
selected from ChEMBL, by querying the compound data
for assay organism as Mycobacterium and standard type as
MIC. Further, target data for M. tuberculosis were
retrieved from binding assays that can be mapped to a sin-
gle target in the M. tuberculosis proteome
We have also extracted small molecule MIC and target
data for M. tuberculosis from the CDD database for TB
(6), and consolidated these data with those ChEMBL
retrieved earlier in order to remove redundancy.
Cheminformatics handling
RDKit (25) has been used to calculate the standard mo-
lecular properties (such as polar surface area, numbers of
hydrogen bond donors and acceptors, molecular weight
and rotatable bonds) and InChI (IUPAC International
Chemical Identifier) for the small molecules. The main
layer InChI, which holds the information about chemical
formulae, atom connections and hydrogen atoms, has been
used to identify the compound duplicates between the data
points obtained from ChEMBL and CDD. Molecular prop-
erties of the small molecules stored in TIBLE were mapped
to their MIC data to highlight regions of chemical space
that are most likely to pass across the cell wall of the
Mycobacterium (see Figure 2A).
Off-target prediction
The computational prediction of the off-site activity is
based on the similarity principle (23). A single therapeutic
candidate shows activity for its intended molecular target,
but is usually seen to have activity against the similar tar-
gets as well. This similarity can be described using both
target-based and ligand-based approaches. In the
Figure 1. Snapshot of the TIBLE database highlighting the type of data stored for mycobacterial species.






/database/article-abstract/doi/10.1093/database/bax041/3866794 by guest on 25 February 2020
structure-based off-target predictions, molecular targets
are linked by the similarity of their pockets (or binding
sites), based on the observation that similar pockets tend to
bind similar molecules (23). In the case of ligand-based
predictions, molecular targets are linked by the similarity
of their ligands, as similar ligands tend to bind to the simi-
lar pockets. The two approaches complement each other
(23) and give a more comprehensive list of possible off-
targets.
We have focused on the ligand-based predictions using
three different methods to predict the possible molecular
off-targets for the small molecules in TIBLE that bind to
M. tuberculosis proteins. These approaches use different
algorithms and rationales but the query data are solely
small molecules (or ligands). The output of the query is a
ranked list of protein targets that are likely to bind the
query ligands. The term ‘target fishing’ (26) has been used
to describe these methodologies.
Figure 2. (A) MIC data points for Mycobacterium tuberculosis extracted from the ChEMBL and Collaborative Drug Discovery databases. (B) Small
molecule binding data mapped to the target protein-Rv1484 in Mycobacterium tuberculosis. This page provides a link to the available protein struc-
tures in the PDB for this target protein, protein structure models in CHOPIN database and also the off-target predictions using the ligand-based
methods.
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The first approach, SEA (Similarity Ensemble
Approach) (27, 28), considers all ligands binding to a par-
ticular target and performs a series of pairwise compari-
sons against a database of targets and their ligands. This
approach has been validated experimentally and has the
advantage that predictions do not correlate with an abso-
lute chemical similarity of the ligands. The second method
used is PharmMapper (29) that uses a database of pharma-
cophores extracted from known drug targets in the PDB
(30). Clustered representative ligands from an M. tubercu-
losis target are aligned with these pharmacophores and the
most likely targets are identified. The advantage of this
method is that it provides a structural interpretation of the
off-target binding. The third method, PASS (31), is a quick
assessment of toxic and undesirable side effects, based on
chemical similarity against a database of small molecules
with known biological activity.
The results of these predictions are accessible in TIBLE
through the target pages. For the M. tuberculosis proteins
that have small molecule binding data, we have a list of
possible off-targets for that protein. For example,
CHEMBL259138 is one of the cluster representatives for
inhA (Rv1484). The top ranked predicted off-target for
this ligand is the cellular retinoic acid-binding protein 2,




The current version of the TIBLE database contains 44 302
MIC data points, for 19 469 unique small molecules active
against 39 nontuberculous and tuberculous mycobacterial
species. Apart from M. tuberculosis, the data points are
included for other mycobacterial species such as M. absces-
sus, M. leprae, M. kansasii, M. intracellulare and M. smeg-
matis. All data in TIBLE are also downloadable as flat text
files.
MIC data can be searched based on the mycobacterial
species of interest and/or the specific MIC type: standard
MIC (MIC), MIC100, MIC90, MIC99, MIC97, MIC95,
MIC80, MIC50 for data that showed 100%, 90%,
99%,97%, 95%, 80% and 50% visual inhibition of the
growth of the Mycobacterium, respectively. MIC data are
also presented in the context of the molecular properties of
the small molecules. Figure 2A exemplifies this by focusing
on the 24 518 MIC data points specific for M. tuberculosis.
By plotting polar surface area vs. the molecular weight, it
is evident that the increase in the size of the molecule is
also accompanied by a general increase in the polar surface
area. This observation is in accordance with the previously
reported observation that antibacterials have high molecu-
lar weight, lower logP and high polar surface area (33).
Intriguingly, there is no correlation of the lipophilicity of
the M. tuberculosis inhibitors with their binding affinities
(a common trend in synthetic-molecule binding data) (34).
The average number of hydrogen bonds and rotatable
bonds increase steadily with the binding affinity
(Figure 2A). Further in-depth analyses are required to
understand these relationships. For example, it has been
shown that highly polar compounds tend to bind to large
binding pockets, for example in riboproteins (33), and this
could explain the profile of antibacterials if many target
this protein class. In addition, natural product-like mol-
ecules also exhibit more polar interactions (35) and this
could contribute to the overall behavior of antituberculosis
compounds if they are predominantly from natural
sources.
Target data
Target activity data for 106 M. tuberculosis protein targets
are included in TIBLE. The target search page allows
M. tuberculosis proteins to be found by RvID, UniProt ID
or common name. There are 3923 binding data points
from 2707 unique small molecules.
Each target page has four tabs: PDB entries correspond-
ing to the respective target id, protein-structure models
from the CHOPIN database, small molecules targeting this
protein and the off-target predictions. The default tab is
linked to the small-molecule activity data, which lists bind-
ing data points with links to original data, two-
dimensional representation of small molecule(s) and a brief
description of the assay. The user can navigate to the other
tabs in the target page to find experimental 3D structures
of the protein target if they are in the PDB (30), or pre-
dicted models from the CHOPIN database (10). Finally the
off-target predictions tab will present the protein off-target
predictions based on the small-molecule binding to that
particular target with the methods already described: SEA
(27, 28), PharmMapper (29) and PASS (31). All these data
can be accessed and downloaded from the website pages.
The M. tuberculosis protein, Rv1484 (inhA), which is
involved in fatty acid biosynthesis pathway and is a well-
studied drug (isoniazid) target for TB (36), has the greatest
number of small molecule binding data points, with activity
recorded for nearly 500 distinct small molecules (Figure 2B).
Web-resource
The TIBLE web site is a lightweight Python web frame-
work. All data extracted from ChEMBL and CCD are
stored in a PostgreSQL database (http://www.postgresql.
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org). SQLAlchemy (http://www.sqlalchemy.org) generates
python objects from the database tables and Flask (http://
flask.pocoo.org) uses these objects to create dynamic
pages. We have used Bootstrap (http://twitter.github.com/
bootstrap) to give the CSS (Cascading Style Sheets) frame-
work and JavaScript functionality to create slick pages.
Conclusion
We present TIBLE, an example of integration of disparate
public data and methods, in order to provide an easy open-
access resource for small-molecule binding data for several
mycobacterial species. It provides data on small-molecules
for their anti-mycobacterial properties, chemical properties
and targets. We believe that TIBLE adds to the existing in-
formation resources for mycobacterial species in a way
that will assist drug development for tackling M. tubercu-
losis infection and managing drug resistance.
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